Saltar al contenido principal
Elsevier

Hypoxia-induced Tumor Heterogeneity and Immune Evasion

Clinical Interventions

  • 1 Edición - 1 de febrero de 2027
  • Última edición
  • Editores: Benjamin Bonavida, Salem Chouaib
  • Idioma: Inglés

Hypoxia-induced Tumor Heterogeneity and Immune Evasion: Clinical Interventions explores how hypoxic stress within the tumor microenvironment drives cancer progression, immune… Leer más

Descripción

Hypoxia-induced Tumor Heterogeneity and Immune Evasion: Clinical Interventions explores how hypoxic stress within the tumor microenvironment drives cancer progression, immune escape, and resistance to therapy. The volume integrates foundational and cutting-edge insights into tumor biology, immunology, and therapeutic innovation. It is structured into five parts, covering tumor heterogeneity, hypoxia-driven mechanisms, immune evasion, clinical diagnostics, and future directions. Topics include metabolic reprogramming, angiogenesis, immune suppression, and hypoxia-targeted therapies, with emphasis on translational relevance.

By bringing together global experts to examine how hypoxia shapes tumor evolution, alters immune responses, and influences treatment outcomes, this resource benefits researchers, clinicians, and advanced students by offering a comprehensive, up-to-date synthesis of a rapidly evolving field. It supports deeper understanding of tumor complexity and equips readers with knowledge to inform experimental design, clinical strategies, and therapeutic development in oncology.

Puntos claves

  • Integrates hypoxia, tumor heterogeneity, and immune evasion to provide a unified framework for understanding resistance mechanisms in cancer
  • Presents cutting-edge research and clinical insights from global experts, offering a comprehensive view of tumor microenvironment dynamics
  • Equips researchers and clinicians with translational strategies to design innovative immunotherapies and improve patient outcomes

De interès para

Researchers in oncology, immunology, and molecular biology.

Índice

  1. Hypoxia-Driven Immune Escape: Molecular Pathways
  2. Hypoxia in Tumour Microenvironment (TME) of Solid Tumours Promotes Tumour Heterogeneity, Immune Suppression, Immune Evasion and Mechanisms of Therapeutic Resistance
  3. Hypoxia-Mediated Immune Evasion Mechanisms in Solid Tumors – Focus on Renal, Pancreatic, Head and Neck, Breast, and Non-Small Cell Lung Cancers
  4. Hypoxia-centered Tumor Ecology: Linking Immunity, Intercellular Communication, and Cellular Plasticity
  5. Hypoxic Niches and Microbiome Dynamics: From Oxygen Deprivation to Functional Metabotypes
  6. Hypoxia-driven mitochondrial remodeling as a source of tumor metabolic heterogeneity and immune escape
  7. Tumor hypoxia, immune evasion, and therapeutic opportunities
  8. Vessel Normalization Mechanisms to Treat Hypoxia-dependent Diseases: The Immunocompetent Microenvironment Challenge
  9. Tumour Hypoxia and Response to Radiotherapy
  10. The role of hypoxia in immune heterogeneity of glioblastoma
  11. Hypoxia gene signatures in cancer: development, biological insights, and clinical translation
  12. Hypoxia-Driven Cancer Progression: Clinical Interventions and Emerging Therapeutic Paradigms
  13. Exploiting Tumor Hypoxia: CP-506 at the Forefront of Hypoxia-Activated Prodrug Development
  14. Future Perspectives and Challenges in Hypoxia, Tumor Heterogeneity, and Immune Resistance

Detalles del producto

  • Edición: 1
  • Última edición
  • Publicado: 1 de febrero de 2027
  • Idioma: Inglés

Sobre los editores

BB

Benjamin Bonavida

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).

Afiliaciones y experiencia
Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, USA

SC

Salem Chouaib

Dr. Salem Chouaib earned his Ph.D. in Immunology from the University of Pierre and Marie Curie (Paris VI) in 1983. He completed postdoctoral training at Memorial Sloan Kettering Cancer Center before joining INSERM and Institut Gustave Roussy, where he became Research Director and led the Tumor Immunology Lab. His research explores killer cell reactivity and tumor microenvironment dynamics, with a focus on hypoxia’s role in immune resistance. A pioneer in cancer immunotherapy, he founded the Thumbay Research Institute for Precision Medicine. Dr. Chouaib has received prestigious awards, including the French League Against Cancer Prize and the Presidential Prize in Biotechnology. He has mentored numerous postdocs, lectures at University Paris-Sud, and has published over 350 scientific works. He also serves as a guest lecturer, journal referee, and scientific advisor globally.
Afiliaciones y experiencia
Research Director, Gustave Roussy Cancer Center, Villejuif, France